U.S. markets close in 3 hours 44 minutes

Novacyt S.A. (NVYTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.98450.0000 (0.00%)
As of 10:48AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.9845
BidN/A x N/A
AskN/A x N/A
Day's Range0.9845 - 0.9845
52 Week Range0.9845 - 5.7700
Avg. Volume96
Market Cap64.567M
Beta (5Y Monthly)-2.65
PE Ratio (TTM)N/A
EPS (TTM)-0.1710
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for NVYTF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: STERIS plcSteris is an Ireland-domiciled medical device company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its 2015 inversion to Ireland, the firm continues to derive roughly 70% of revenue from its U.S. operations, 10% from the United Kingdom, and the remaining 20% from other international regions.
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • Business Wire

    Launch of Novacyt’s first fully lyophilised PROmate® assays

    PARIS & CAMBERLEY, England, August 04, 2022--Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) ("Novacyt", the "Company" or the "Group"), an international specialist in clinical diagnostics, announces the launch of the Company’s first fully lyophilised (freeze-dried), direct-to-PCR assays. This new class of PROmate® assay enables shipping and transportation at ambient temperatures to remote regions or in areas without a centralised cold storage supply chain, providing an extended glob

  • Business Wire

    Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Launch of Research-Use-Only Adenovirus F41 Assay

    PARIS & CAMBERLEY, England, July 28, 2022--Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of a research-use-only (RUO) polymerase chain reaction (PCR) assay for the detection of adenovirus F41, in response to recent cases of acute hepatitis in children. This launch expands Novacyt’s genesig® real-time PCR diagnostic product portfolio and is in line with the Company’s strategy to maintain its position as a gl

  • Business Wire

    Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Approval of exsig™ COVID-19 Direct Test in the UK Under CTDA Legislation

    PARIS & CAMBERLEY, England, July 15, 2022--Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s exsig™ COVID-19 Direct Real-Time PCR test has been approved in the UK under the UK Health Security Agency's Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 ("CTDA").